| Autor: |
Warshaw EM; From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA.; Department of Dermatology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.; Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA., Peterson MY; From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA.; Department of Dermatology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA., DeKoven JG; Division of Dermatology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada., Adler BL; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Pratt MD; Division of Dermatology, University of Ottawa, Ontario, Canada., Belsito DV; Department of Dermatology, Columbia University Irving Medical School, New York, New York, USA., Atwater AR; Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA., Houle MC; Division of Dermatology, Centre Hospitalier Universitaire de Québec, Laval University, Québec, Canada., Dunnick CA; Department of Dermatology, Rocky Mountain Regional VAMC, Aurora, Colorado, USA., Yu J; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Taylor JS; Department of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA., Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Reeder MJ; Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA., DeLeo VA; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Mowad C; Department of Dermatology, Geisinger Medical Center, Danville, Pennsylvania, USA., Botto NC; Department of Dermatology, University of California San Francisco, San Francisco, California, USA. |
| Abstrakt: |
Background: Mentha piperita (MP; peppermint) oil has many commercial uses. Objective: To characterize the epidemiology of contact allergy to MP oil 2% petrolatum. Methods: Retrospective analysis of North American Contact Dermatitis Group data (2009-2020). Results: Of 28,128 patients tested to MP, 161 (0.6%) had an allergic reaction. Most allergic patients were female (77.0%) and/or over 40 years of age (71.4%). The most common anatomical sites of dermatitis included face (31.7%; of these, one-third specified lips), hands (17.4%), and scattered/generalized (18.6%). Nearly one-third (30.4%) of reactions were strong (++)/extreme (+++), and 80.1% were considered currently relevant. Common sources included oral hygiene preparations, foods, and lip products. Co-reaction with at least 1 of the other 19 fragrance/plant-related screening test preparations occurred in 82.6% (133/161) of MP-allergic patients, most commonly Cananga odorata oil (42.9%), fragrance mix I (41.0%), hydroperoxides of linalool (35.7%), Compositae mix (35.4%), Jasminum officinale oil (31.9%), Myroxylon pereirae (31.7%), and propolis (28.1%). Co-reaction with at least 1 of the 3 most commonly used fragrance screening allergens (fragrance mix I, fragrance mix II, and/or Myroxylon pereirae ) was 59.6%. Conclusions: Twelve-year prevalence of MP allergy was 0.6%. Approximately 40% of cases would have been missed if only fragrance screening allergens were tested. |
